GTI, Edinburgh, UK
Tuesday 22 November 2005
Pathway biology is transforming biomedical research at the molecular level. The traditional study of single genes, proteins and small molecules is joined by attempts to understand how many of these components interact in ‘molecular pathways’. What does this mean for the patient? How will these scientific insights be translated into practical applications in healthcare?Conference Programme 09.00-09.15 - Welcome & Introduction Session 1:
09.15-09.45 - Dr Declan Doogan, Pfizer Global Research & Development:
“Pathways in Healthcare” 09.45-10.15 - Professor Igor Goryanin , Bioinformatics, University of
Edinburgh:
“Pathway Computational Mapping” 10.15-10.45 - Dr Adriano Henney, Astrazeneca:
“The Application of Pathway Analytical Tools in Drug Discovery & Development” Break:
10.45-11.15 – Refreshments & Posters Session 2:
11.15-11.45 - Dr William S Marshall, Dharmacon:
“Applications of siRNA Silencing in Drug Discovery & Systems Biology” 11.45-12.15 - Professor Ferran Sanz, INFOBIOMED, Universitat Pompeu Fabra:
“Chemistry, Cheminformatics & Pathways” 12.15-12.45 - Dr John Lamb, Merck/Rosetta:
“Inferring Causal Associations Between Genes and Diseases” Break: 12.45-14.00 - Lunch, Exhibition & Posters Session 3:
14.00-14.30 - Dr David J Hayes, Upstate Ltd., A Serologicals Company:
“Kinase Pathways” 14.30-15.00 - Dr Padma Reddy, Wyeth Research:
“Integrating Pathway Analysis with Expression Profiling” Break:
15.00-15.30 – Refreshments & Posters Session 4:
15.30-16.00 - Professor Peter Ghazal, GTI, University of Edinburgh:
“Systematics of Pathways” 16.00-16.30 - Professor Christopher Price, Bayer Healthcare:
“Clinical Diagnostics; From Science to Health Outcomes” Networking Reception:
16.30-19.00 – Sponsored by Dharmacon/Perbio Science UK
Who Should Attend?
• All scientists, from academia and industry, with an interest in pathway approaches and translational medicine • Medical practitioners with a desire to translate this science into clinical benefit • Students, who wish to get an understanding of this exciting area • Advisors and policy makers, to inform their decision-making
|